<i>Trans</i>‐3,5,4´‐trimethoxystilbene reduced gefitinib resistance in <scp>NSCLC</scp>s via suppressing <scp>MAPK</scp>/Akt/Bcl‐2 pathway by upregulation of miR‐345 and miR‐498

Min Lu(South China Agricultural University), Ping Liu(Capital Medical University), Fang Wu(Central South University), Bin Liu(Sun Yat-sen University), Chunhong Hu(Central South University), Hui Xiong(Central South University)
Journal of Cellular and Molecular Medicine
January 30, 2019
10.1111/jcmm.14086
Cited by 40

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application
|Clinical Epigenetics|2021|253
Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis
|Molecular & Cellular Proteomics|2007|247
Macroscopic somatic clonal expansion in morphologically normal human urothelium
|Science|2020|221